Search research articles
Contact Us
Filters
Showing results (341-350 of 499) with videos related to
Page
of 50
Sort By:
EJNMMI Research
|
June 1, 2023
Prospective comparison of [<sup>18</sup>F]AlF-NOTA-octreotide PET/MRI to [<sup>68</sup>Ga]Ga-DOTATATE PET/CT in neuroendocrine tumor patients
Lennert Boeckxstaens, Elin Pauwels, Vincent Vandecaveye, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 16, 2014
A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors
Philippe L Bedard, Josep Tabernero, Filip Janku, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 28, 2026
Sex differences in efficacy and toxicity of first-line treatment of metastatic colorectal cancer: An analysis of 18,041 patients in the ARCAD CRC database
Anna Dorothea Wagner, Morteza Raeisi, Manel Rakez, et al.
Cancer Science
|
October 22, 2017
Everolimus in advanced, progressive, well-differentiated, non-functional neuroendocrine tumors: RADIANT-4 lung subgroup analysis
Nicola Fazio, Roberto Buzzoni, Gianfranco Delle Fave, et al.
The Oncologist
|
March 10, 2017
Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer
Rocío García-Carbonero, Eric van Cutsem, Fernando Rivera, et al.
Digestion
|
February 20, 2003
Gastric electrical stimulation in intractable symptomatic gastroparesis
Thomas L Abell, Eric Van Cutsem, Hasse Abrahamsson, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
|
July 21, 2014
HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer
Eric Van Cutsem, Yung-Jue Bang, Feng Feng-Yi, et al.
Journal of Neuroendocrinology
|
June 5, 2024
Clinical impact of using [<sup>18</sup>F]AlF-NOTA-octreotide PET/CT instead of [<sup>68</sup>Ga]Ga-DOTA-SSA PET/CT: Secondary endpoint analysis of a multicenter, prospective trial
Hannes Leupe, Elin Pauwels, Timon Vandamme, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 26, 2011
Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting
Matthew H Kulke, Lillian L Siu, Joel E Tepper, et al.
JAMA
|
October 28, 2010
Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab
Wendy De Roock, Derek J Jonker, Federica Di Nicolantonio, et al.
Page
of 50
Search research articles
Search
Showing results (341-350 of 499) with videos related to
Sort By:
Page
of 50
EJNMMI Research
|
June 1, 2023
Prospective comparison of [<sup>18</sup>F]AlF-NOTA-octreotide PET/MRI to [<sup>68</sup>Ga]Ga-DOTATATE PET/CT in neuroendocrine tumor patients
Lennert Boeckxstaens, Elin Pauwels, Vincent Vandecaveye, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 16, 2014
A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors
Philippe L Bedard, Josep Tabernero, Filip Janku, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 28, 2026
Sex differences in efficacy and toxicity of first-line treatment of metastatic colorectal cancer: An analysis of 18,041 patients in the ARCAD CRC database
Anna Dorothea Wagner, Morteza Raeisi, Manel Rakez, et al.
Cancer Science
|
October 22, 2017
Everolimus in advanced, progressive, well-differentiated, non-functional neuroendocrine tumors: RADIANT-4 lung subgroup analysis
Nicola Fazio, Roberto Buzzoni, Gianfranco Delle Fave, et al.
The Oncologist
|
March 10, 2017
Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer
Rocío García-Carbonero, Eric van Cutsem, Fernando Rivera, et al.
Digestion
|
February 20, 2003
Gastric electrical stimulation in intractable symptomatic gastroparesis
Thomas L Abell, Eric Van Cutsem, Hasse Abrahamsson, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
|
July 21, 2014
HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer
Eric Van Cutsem, Yung-Jue Bang, Feng Feng-Yi, et al.
Journal of Neuroendocrinology
|
June 5, 2024
Clinical impact of using [<sup>18</sup>F]AlF-NOTA-octreotide PET/CT instead of [<sup>68</sup>Ga]Ga-DOTA-SSA PET/CT: Secondary endpoint analysis of a multicenter, prospective trial
Hannes Leupe, Elin Pauwels, Timon Vandamme, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 26, 2011
Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting
Matthew H Kulke, Lillian L Siu, Joel E Tepper, et al.
JAMA
|
October 28, 2010
Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab
Wendy De Roock, Derek J Jonker, Federica Di Nicolantonio, et al.
Page
of 50